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Streszczenie
Wstęp: Długoterminowa skuteczność farmakologicznego
leczenia nadczynności tarczycy w przebiegu choroby Gra-
vesa-Basedowa nadal pozostaje niezadowalająca i trudna
do przewidzenia. Celem niniejszego badania była ocena
przydatności oznaczeń przeciwciał blokujących wiązanie
tyreotropiny (TBII) z receptorem w przewidywaniu możli-
wości nawrotu nadczynności tarczycy już we wczesnej
fazie leczenia farmakologicznego.
Materiał i metody: Badaniem objęto 37 chorych z pierw-
szym incydentem nadczynności tarczycy w przebiegu cho-
roby Gravesa-Basedowa w wieku 20–60 lat. Wszystkich
chorych leczono tiamazolem przez okres 12 miesięcy. Przed,
a następnie po 1, 3, 6, 9 i 12 miesiącach terapii dokonywano
oceny klinicznej, ultrasonograficznego badania tarczycy
i oznaczenia TBII (test II generacji) oraz tyreotropiny, wol-
nej trijodotyroniny i wolnej tyroksyny w surowicy.
Wyniki: Okres obserwacji po odstawieniu leku wynosił
średnio 27,24 ± 5,81 miesięcy. U dwunastu z 37 chorych
nastąpił nawrót nadczynności tarczycy po średnio 8,17 ±
± 6,91 miesiąca od zakończenia leczenia. Znacząca różnica
w poziomach TBII w grupie chorych pozostających w remisji
i chorych, u których doszło do nawrotu choroby widoczna
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była od pierwszego miesiąca terapii przez cały jej okres trwa-
nia. U chorych z TBII > 14 IU/l po 3 miesiącach oraz u cho-
rych z TBII > 8 IU/l po 6 miesiącach leczenia znacznie
częściej dochodziło do nawrotu nadczynności tarczycy
w porównaniu z chorymi z niższymi poziomami TBII (czu-
łość 50% i specyficzność odpowiednio 92% i 96%).
Wnioski: Oznaczanie TBII we wczesnej fazie leczenia far-
makologicznego może okazać się pomocne w planowaniu
dalszego leczenia nadczynności tarczycy i w odpowiednio
wczesnym kwalifikowaniu chorych do bardziej radykalnych
form terapii nadczynności tarczycy w przebiegu choroby
Gravesa-Basedowa (terapia radiojodem, strumektomia).
(Endokrynol Pol 2006; 6 (57): 596–604)
Słowa kluczowe: choroba Gravesa-Basedowa, nadczynność
tarczycy, autoprzeciwciała, receptor TSH, TBII.
597
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 57; Numer/Number 6/2006
ISSN 0423–104X
Predicting a relapse of Graves’ hyperthyroidism in adults during
the early phase of treatment with anti-thyroid drugs
Marta Jonas1, Urszula Ambroziak2, Tomasz Bednarczuk1, Janusz Nauman1,  2
1Department of Endocrinology, M. Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw
2Chair and Department of Internal Medicine and Endocrinology, Medical University, Warsaw
Janusz Nauman, M.D., Ph.D.
Department of Endocrinology, M. Mossakowski Medical
Research Center, Polish Academy of Sciences
Pawińskiego 5, 02–106 Warszawa
phone: 022 599 29 75, fax: 022 599 19 75
e-mail: janu@amwaw.edu.pl

Abstract
Introduction: The long-term effectiveness of anti-thyroid
drugs (ATD) in the treatment of Graves’ hyperthyroidism
(GH) is still unsatisfactory and difficult to predict.
The aim of this study was to evaluate the usefulness of
a determination of serum level of thyrotropin-binding in-
hibiting immunoglobulins (second generation TBII assay)
in predicting the possibility of relapse in the early phase of
pharmacological treatment.
Material and methods: We investigated 37 patients within
the 20–60 age range with the first occurrence of GH. All
patients were treated with thiamazole for 12 months. Clini-
cal assessment, ultrasound estimation of thyroid volume and
determination of serum thyrotropin, free thyroxine, free
triiodothyronine, thyroid autoantibodies and TBII levels
were carried out at the onset and after 1, 3, 6, 9 and 12 mon-
ths of ATD treatment.
Results: The mean follow-up period after ATD withdrawal
was 27.24 ± 5.81 months. Of 37 patients 12 (32%) had a re-
lapse of hyperthyroidism (mean time 8.17 ± 6.91 months
after drug withdrawal). The difference in TBII levels betwe-
en the relapse and the remission group was found to be
Introduction
Graves’ hyperthyroidism (GH) is an autoimmune, or-
gan-specific disorder caused by thyroid-stimulating
antibodies that lead to increased thyroid hormone pro-
duction [1–3]. In the majority of European countries,
including Poland, anti-thyroid drugs (ATD) are the first
choice therapy in newly diagnosed patients with Gra-
ves’ hyperthyroidism (GH) [4]. The main problem of
ATD therapy, however, is its unsatisfactory long-term
effectiveness, resulting in a relapse of up to 60% in pro-
perly qualified and treated patients [5–9].
In the past the long-term effect of ATD treatment
was anticipated by evaluating several clinical or labora-
tory parameters. These parameters were age, gender,
serum level of thyroid stimulating autoantibodies (TSAb
and thyrotropin-binding inhibitory immunoglobulins),
TBII, TSH, free T3/free FT4 ratio, (the FT3/FT4 ratio),
thyroid volume, thyroid echogenicity, thyroglobulin,
significant after the first month of therapy until the end of
ATD treatment. We observed that patients with TBII above
14 IU/L after 3 months and above 8 IU/L after 6 months of
therapy relapsed more frequently than patients with lower
levels (sensitivity 50% and specificity 92 and 96%, respecti-
vely).
Conclusions: The study confirmed that TBII estimation in
the early phase of ATD could be useful in the proper plan-
ning of GH therapy and early qualification to more radical
treatment (radioiodine or surgery).
(Pol J Endocrinol 2006; 6 (57): 596–604)
Key words: Graves’ disease, hyperthyroidism, autoantibodies,
TSH receptor, TBII
anti-thyroperoxidase autoantibodies (aTPO) and anti-
thyroglobulin antibodies (aTG) [10–25]. Although the-
se parameters, either alone or as a group of tests, were
found to have some prognostic value, none of them
exhibited satisfactory sensitivity, specificity or reprodu-
cibility. Moreover, the prognostic value of all of them
was evaluated before or after completion of long-term
ATD treatment [14, 26, 27]. During recent years a new
assay system with human recombined TSH receptor
immobilised either on plastic tubs or ELIZA plate wells
has been introduced to measure the level of TBII in se-
rum [28–30]. This test used in GH patients was soon
found to be more sensitive and specific than the first
generation assay [31–34]. Moreover, data recently pu-
blished [28, 35–38], including our own results [39], have
all confirmed that the present TBII assay indirectly es-
timates the presence of TSAb.
The aim of this study was to evaluate the useful-
ness of the second generation TBII in predicting the
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long-term outcome of the therapy in the early phase of
pharmacological treatment. In addition, we have also
investigated whether some of the clinical or hormonal
parameters can enhance the predictive value of TBII
measurements during the first months of ATD treatment.
Material and methods
Patients
We enrolled consecutively patients with newly diagno-
sed yet untreated Graves’ hyperthyroidism, referred by
general practitioners to the outpatient clinic of the De-
partment of Endocrinology, Warsaw Medical Univer-
sity. The exclusion criteria for the study were: large go-
itre (volume > 75 ml), age below 20 years, ongoing pre-
gnancy, breast-feeding or the coexistence of serious ill-
ness. Patients with severe Graves’ ophthalmopathy
(GO) of NOSPECS class IV and higher were also exclu-
ded, as they could require immunosuppressive thera-
py. The diagnosis of Graves’ hyperthyroidism was con-
firmed according to commonly accepted clinical, hor-
monal and immunological criteria [40].
Study protocol
All patients were initially treated with 40 mg of thiamazo-
le (Thyrozol, Merck, Darmstadt, Germany) for one month
and then the dose was reduced to the lowest required
to maintain euthyroid status (usually 5–10 mg/day). The
treatment period was 12 months. Clinical assessment
(expressed as a Crooks’ index), ultrasound estimation
of thyroid volume, laboratory tests (serum TSH, FT4 and
FT3) and determination of thyroid autoantibodies
(aTPO, aTG) and TBII levels in serum were carried out
at the onset and after 1, 3, 6, 9 and 12 months of ATD
treatment. The shortest follow-up period after ATD
withdrawal was 18 months. Relapse of Graves’ hyper-
thyroidism was defined as a Crooks’ index grade above
5.0 and serum FT4 and FT3 levels above normal. The
study was approved by the Ethical Committee of War-
saw Medical University and all patients gave their writ-
ten informed consent.
Clinical parameters and biochemical
measurements
Crooks’ index was calculated as previously described
[41]. Serum TSH, FT3 and FT4 concentrations were de-
termined by microparticle enzyme immunoassays
(AxSym System, Abbott, Chicago, USA). Normal ran-
ges were 0.49–4.67 µIU/ml, 1.45–3.48 pg/ml and 0.71–
–1.85 ng/dl, respectively. Serum FT3 results in pg/ml co-
uld be converted to the International System Units by
multiplying by 1.536 and serum FT4 results in ng/dl
by multiplying by 12.872. FT3/FT4 ratio was calculated
according to the formula (pg/ml: ng/dl) × 10 [42]. Hu-
man TSH receptor autoantibodies (TBII) were determi-
ned by second-generation luminescence receptor assay
(B.R.A.H.M.S Diagnostica GmbH, Henningsdorf, Germa-
ny). TBII values above 1.5 IU/l were defined as positive.
Antibodies against native human thyroglobulin (aTG)
and antibodies against native human thyroid peroxida-
se (aTPO) were determined by luminescence immuno-
assays (B.R.A.H.M.S. Diagnostica GmbH, Henningsdorf,
Germany) with positive values > 60 U/l in both assays.
Statistical analysis
The statistical analysis was performed using Statistica
for Windows. Data were analysed by the non-parame-
tric Mann-Whitney U-test, Wilcoxon matched pairs test
and c2 test.
Results
Baseline characteristics
We enrolled 41 patients (36 women, 5 men), aged
20–60 years (with a mean age of 41.0). Of these 37 pa-
tients (32 women and 5 men), aged 20–60 years (mean
age 41.0) completed the study, 4 patients having drop-
ped out because they had moved out of the district. The
clinical characteristics of the group studied before ATD
treatment are shown in Table I.
Relapse rates (outcome)
The majority of patients responded to the ATD treat-
ment within the first month in terms of clinical impro-
vement (Crooks’ index) and serum TSH, FT4 and FT3
results. However, 9 patients (23.68%) were still slightly
Table I
Characteristics of the group of patients as a whole before ATD
therapy
Tabela I
Charakterystyka całej grupy pacjentów przed terapią
tyreostatykiem
Parameter No. of patients (% of whole
group)/Median (range)
Graves’ ophthalmopathy 9 (24.32%)
Smokers 14 (35.14%)
Family history of AITD 14 (35.14%)
Crooks’ index 23 (8–31)
TBII [IU/l] 7.52 (0.00–75.00)
TSH [mIU/l] 0.00 (0.00–0.04)
FT4 [ng/dl] 4.07 (1.5–8.6)
FT3 [pg/ml] 13.52 (4.55–31.42)
FT3/FT4 32.10 (2.94–83.80)
Thyroid volume (ml) 17.41 (7.00–74.03)
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hyperthyroid (Crooks’ index > 5.0, with typically low
serum TSH and both serum FT3 and FT4 elevated). After
3 months of ATD all those investigated became clinical-
ly euthyroid, with serum FT4 and FT3 within the nor-
mal range. TSH levels in the sera of 5 patients, howe-
ver, were suppressed and remained so until month
12th of therapy. In contrast to the clinical improvement
seen from month 3rd of treatment in all patients, the nor-
malisation of serum TBII level (immunological remis-
sion) was achieved only in 20 patients (54.05%). The
mean follow-up period after ATD withdrawal was
27.24 ± 5.81 months. A relapse of hyperthyroidism oc-
curred in 12 patients (32%), 9 female, 3 male, out of 37.
The mean time of relapse after drug withdrawal in the
group of patients as a whole was 8.17 ± 6.91 months.
Within the first 6 months 6 patients (16%) had relap-
sed, while the remaining 6 patients relapsed within
13 months of the follow-up period.
Prediction of the relapse
a. TBII levels. Although before treatment TBII levels
were higher in the relapse group compared to the
remission group, the difference was not significant
(19.7 ± 24.5 vs. 8.85 ± 7.64, p = 0.30) (Fig. 1). Howe-
ver, the difference in TBII levels became significant
after the first month of therapy and remained signi-
ficant (p < 0.01) until the end of ATD treatment
(Fig. 1). It is of interest that in the relapse group the
TBII level increased slightly during first month of
treatment and was higher after 3 months of therapy
than at the initial diagnosis. All patients in the re-
lapse group had positive TBII levels during the
12 months of treatment. In contrast to this, in the
remission group positive TBII values were observed
in 25 patients (100%) after 1 month of treatment.
Serum TBII levels decreased gradually in most pa-
tients from the remission group and we observed
normalisation of TBII in 2 patients after 3 months of
ATD, in 8 patients after 6 months, in 16 patients after
9 months and in 17 patients after 12 months of ATD
in this group of patients.
Moreover, the median TBII level from the onset of
GH in patients who relapsed very early after drug wi-
thdrawal was 16.29 IU/L (mean 22.56 ± 19.59) and was
significantly higher than that observed in patients who
relapsed later in the follow-up period (median 3.21 IU/l,
mean 16.80 ± 28.94).
The median TBII levels observed in the relapse group
before and during 12 months of the ATD were used to
evaluate the predictive value of TBII for the relapse of
hyperthyroidism (Tab. II). As shown, sensitivity in the
prediction of the relapse reached 50 % at the beginning of
ATD and was stable, but specificity, which was 80% at the
beginning, had already reached over 90 % after the third
month of the therapy. Figure 2 shows individual TBII le-
vels during ATD therapy in patients who relapsed.
b. aTPO and aTG. We observed elevated aTPO levels
in 31 patients (83.78%): 21 from the remission group
7.12
1.32
12.18
17.15
6.53
4.54*
1.53* 1.23*
6.38
13.78*
8.02*
4.95*
0
4
8
IU
/L
12
16
20
0 1 3 6 9 12 months
ns p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Remission Relapse group
Figure 1. TBII medians in the remission and the relapse groups before and during 12 months of ATD therapy; *denotes a significant
decrease in comparison with prior value
Rycina 1. Mediany TBII w grupie chorych pozostających w remisji i w grupie chorych z nawrotem nadczynności tarczycy przed
i w trakcie 12 miesięcy terapii tyreostatykiem; *oznacza statystycznie znaczące zmniejszenie w porównaniu z wartością obserwowaną
w poprzednim punkcie czasowym terapii
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(84.00%) and 10 from the relapse group (83.30%).
Elevated aTG was identified in 20 patients (54.05%): in
23 patients (52.00%) from the remission group and in
7 (58.33%) from the relapse group. After 12 months of
therapy the percentage of positive aTPO and aTG le-
vels decreased but the analysis performed did not pro-
vide any significant data for predicting the results of
therapy in the early phase of ATD treatment.
c. TSH, FT4, FT3. There was no statistical difference
between the groups in TSH, FT4, and FT3 values.
However, after 12 months TSH remained suppres-
sed in 4 patients in the relapse group compared to
one patient from the remission group. When the
values of the FT3/FT4 ratio were analysed a signifi-
cant decrease in the FT3/FT4 ratio in the remission
group was already observed after the first month of
ATD therapy, while a similar decrease in the relap-
se group was seen much later, not until the month 9
of the therapy, for example (Fig. 3).
d. Thyroid volume. Although thyroid volume tended
to be greater in the relapse group compared to the
remission group, the differences before the therapy
were not statistically significant (Fig. 4). Goitre (de-
fined as a thyroid volume above 20 ml in women
and 25 ml in men) was observed at the beginning in
58.33% of patients in the relapse group and in 28.00%
in the remission group. The incidence of goitre de-
creased in both groups of patients at the end of tre-
atment and reached 41.67% in the relapse group and
8.00% in the remission group.
e. Graves’ ophthalmopathy (GO). Analysis performed
for finding clinical predictors of the long-term
effect of treatment showed that the presence of GO
was significantly more frequent in the group of
Table II
Prediction of hyperthyroidism relapse on the basis of TBII values. medians in the relapse group (n=12) during consecutive
months of antithyroid therapy
Tabela II
Rokowanie nawrotu nadczynności tarczycy na podstawie wartości TBII (mediany) w grupie chorych z nawrotem nadczynności
tarczycy w czasie kolejnych miesięcy terapii tyreostatykiem
Months of ATD therapy TBII * No. of all patients with Sensitivity Specificity Positive Negative
[IU/l] given TBII value/ no. of (%) (%) predictive predictive
patients who relapsed value value
with given TBII value (PPV) (NPV)
Before ≥ 12 11/6 50 80 55 77
1 ≥ 17 9/6 50 88 67 79
3 ≥ 14 8/6 50 92 75 79
6 ≥ 8 7/6 50 96 86 80
9 ≥ 5 7/6 50 96 86 80
12 ≥ 6 7/6 50 96 86 80
0
5
10
15
20T
BI
I I
U/
L 25
30
35
40
45
0 1 3 6 9 12
Months of ATD
Figure 2. Dynamics of TBII value in each patient from the relapse
group during 12 months of ATD treatment. Black bars denote
median TBII value at a particular point of ATD therapy. Normal
upper TBII level 1.5 IU/L
Rycina 2. Dynamika wartości TBII w ciągu 12 miesięcy terapii
u chorych z grupy nawrotu nadczynności tarczycy. Czarne
prostokąty oznaczają mediany TBII w poszczególnych miesiącach
terapii tyreostatykiem. Wartość negatywna TBII < 1,5 IU/l
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Figure 3. Different dynamics of FT3/FT4 ratio values (medians) in the remission and relapse groups before and during ATD therapy;
*denotes a significant decrease in comparison with prior value
Rycina 3. Dynamika wartości median wskaźnika FT3/FT4 w grupie chorych pozostających w remisji i w grupie chorych z nawrotem
nadczynności tarczycy przed i w trakcie 12 miesięcy terapii tyreostatykiem; *oznacza statystycznie znaczące zmniejszenie w porównaniu
z wartością obserwowaną w poprzednim punkcie czasowym terapii
Figure 4. Thyroid volume (medians) in the remission and relapse groups of patients during 12 months of ATD therapy; *denotes
a significant decrease in comparison with prior value
Rycina 4. Objętość tarczycy (mediana) w grupie chorych pozostających w remisji i w grupie chorych z nawrotem nadczynności tarczycy
przed i w trakcie 12 miesięcy terapii tyreostatykiem; *oznacza statystycznie znaczące obniżenie w porównaniu z wartością obserwowaną
w poprzednim punkcie czasowym terapii
patients with relapse of hyperthyroidism (50% vs
12%, p < 0.01).
The relapse and remission group did not differ
in age, gender, tobacco smoking or family history of
Graves’ disease. The addition of the clinical and hor-
monal parameters investigated did not significantly
enhance the possibility of prediction established by
TBII level.
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Discussion
The ability to predict the outcome of ATD therapy in pa-
tients with Graves’ disease has proved to be a difficult task.
Nevertheless, several clinical symptoms and laboratory
findings have been analysed in the past to identify pa-
tients who are likely to achieve long-term remission.
The prospective good responder to ATD treatment
is female rather than male [43, 44], older than 30 years
[10, 45] and has a thyroid volume either of normal size
or only moderately enlarged [10]. The serum TBII level
in such a patient should be only mildly increased [10–
–13, 15, 16] and the serum thyroxine (T4) to triiodothy-
ronine (T3) ratio should be below 20 [11, 18, 19]. In ad-
dition, the patient should not have a history of Graves’
disease among his or her closest relatives [46], should
be a non-smoker [47] and should have no signs of infil-
trative ophthalmopathy [48] or thyroid dermopathy [49].
Nevertheless, even a patient matching these criteria
would have no absolute confidence that long-term re-
mission would be achieved. Most studies predicting the
outcome of ATD treatment were performed after ter-
mination of ATD therapy [14, 25–27, 50, 51]. The results
of these studies indicated that serum TSH and the level
of TBII estimated in a group of patients with GH are
both useful as markers of relapse or remission [27, 44],
although in the individual patient either the concen-
tration of TSH or the level of TBII may fail as an absolu-
te predictor.
Lack of stable remission after long-term treatment
decreases the quality of life and imposes an economic
burden for both the patient and the public health sys-
tem. In the present study, therefore, we were tempted
to find out whether TBII measurements could be used
to predict the relapse of hyperthyroidism at the early
stage of treatment. Indeed, our results have confirmed that
prediction before treatment is premature. On the other
hand, we have shown that serum levels of TBII can pre-
dict the risk of relapse with 50% sensitivity and 96% speci-
ficity after 6 months of ATD treatment. Our group of pa-
tients was relatively homogenous; we included only the-
se with the first onset of Graves’ hyperthyroidism and
excluded very young patients, those with very large go-
itre or the nodular variant of Graves’ disease.
As has been shown, we were unable to demonstrate
the presence of a correlation between the relapse of
hyperthyroidism, age, gender, smoking and a family
history of autoimmune thyroid disease, as was previo-
usly revealed [10, 43, 46, 48, 52, 53]. Similarly, a value
above 55 of the FT3/FT4 ratio, suggested as a common
phenomenon in GH [42], appeared only in a few pa-
tients in our group (8%). It is important, however, to
underline the significant decrease in the FT3/FT4 ratio
in our remission group after the first month of therapy.
On the other hand, we confirmed previous findings
[48] that the coexistence of GO is much more frequent
among patients who relapse after drug withdrawal. In
5 of our patients (13.51%) serum TSH remained almost
totally suppressed (< 0.1 µIU/ml) until the end of the
therapy, regardless of serum FT3 and FT4 normalisa-
tion. This might be explained by the interaction of TBII
with the TSH receptor on thyrotrophs in the anterior
pituitary [54], as all the patients had a positive result in
TBII estimation (range 1.57–37.80 IU/L) This range of
TBII can also confirm the heterogeneity of these auto-
antibodies [55–57].
It is of interest that the relapse in our patient with
suppressed TSH was seen soon after ATD withdrawal.
Such findings are compatible with previous [5, 58] and
very recent [27] observations, that TSH concentration
measured at the end of pharmacological treatment of
hyperthyroidism is a very reliable predictor of relapse.
Our data also suggest that a smooth increase in TBII
levels in a very early phase of pharmacological therapy
could be a predictor of relapse. This observation seems
to be in accordance with the results presented by Taka-
su et al., who, on the other hand, identified a smooth
decrease in TBII levels in the early phase of medical the-
rapy as reliable predictor of stable remission of GH [59].
In addition, our results show that a considerable decre-
ase in TBII, aTPO and aTG levels was observed only
during the first 9 months of treatment and no further
decrease was observed during the last 3 months of the-
rapy. This is in agreement with the results of Edan et al.
[60]. In 2 patients we observed a relapse despite negati-
ve TBII levels. The mechanism of relapse in such a situ-
ation remains unclear, but Mukuta et al. [61] reported
a similar finding.
In summary, we suggest that measurement of
TBII by the second generation assay helps in making
a preliminary prediction of long-term outcome of ATD
treatment in a relatively early phase of therapy. Altho-
ugh TBII is no absolute indicator of relapse in individu-
al cases, we believe that unfavourable results with re-
spect to assessment for these autoantibodies should
be presented to the patient as leading to the conclu-
sion that the chances of stable remission after 12 mon-
ths of therapy are low and that a more radical type of
therapy (radioiodine or surgery) should be conside-
red. In another words, we believe that the high level
of specificity of TBII determination allows patients to
be identified who have little or no likelihood of achie-
ving and maintaining long term remission of Graves’
disease after ATD therapy. Our results also suggest that
a combination of TBII values and thyroid volume, FT3/
/FT4 ratio levels or aTG concentrations does not assist
prediction of a relapse of hyperthyroidism at the early
stage of ATD treatment.
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In conclusion: determination of TBII level alone at
a relatively early stage of ATD treatment allows the
chances of stable remission of hyperthyroidism to be
evaluated in 50% of Graves’ patients and is therefore
helpful in the appropriate planning of disease manage-
ment.
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